No Data
Favourable Signals For Cutera: Numerous Insiders Acquired Stock
Global Non-invasive Aesthetic Treatment Market Analysis Report 2024-2032 Featuring Johnson & Johnson, Bausch, Cutera, AbbVie, Sisram Medical, Galderma, Sientra, and Revance Therapeutics
Stephens & Co. Reiterates Overweight on Cutera, Maintains $10 Price Target
Stephens & Co. analyst George Sellers reiterates Cutera (NASDAQ:CUTR) with a Overweight and maintains $10 price target.
Cutera Is Maintained at Neutral by Piper Sandler
Cutera Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Neutral on Cutera, Maintains $3 Price Target
Piper Sandler analyst Matt O'Brien maintains Cutera with a Neutral and maintains $3 price target.
Cutera Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/21/2024 62.16% Piper Sandler $3 → $3 Maintains Neutral 03/22/2024 440.54% Stephens & Co. → $10 Reiterat